Market Cap 433.49M
Revenue (ttm) 0.00
Net Income (ttm) -2.06M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 302,500
Avg Vol 103,406
Day's Range N/A - N/A
Shares Out 7.04M
Stochastic %K 32%
Beta -6.17
Analysts Strong Sell
Price Target $81.00

Company Profile

Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio of selective 5-HT receptor agonists includes 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry; and BMB-101 which completes phase 1 trial for undisclosed seizure disorder. The company also develops BMB-201 and BMB-202 for the treatment of neuropsychiatry and neurology indicatio...

Industry: Biotechnology
Sector: Healthcare
Phone: 647 865 8622
Address:
19 Vestry Street, New York, United States
soulsearche
soulsearche Oct. 24 at 3:39 PM
$NEUP $TOVX run up is to distract biotech memes away from $NEUP.......$DRUG in making here. you heard it first here
1 · Reply
Builder46
Builder46 Oct. 23 at 3:28 PM
0 · Reply
topstockalerts
topstockalerts Oct. 23 at 3:17 PM
$DRUG Keep an eye for upcoming plays
0 · Reply
laurenlee
laurenlee Oct. 23 at 3:09 PM
$SCNX That was. $DRUG
0 · Reply
ghostrider007
ghostrider007 Oct. 23 at 3:07 PM
$SCNX $DRUG fkkk thatll be amazing
0 · Reply
laurenlee
laurenlee Oct. 23 at 3:06 PM
$SCNX $DRUG Two One hundred
0 · Reply
laurenlee
laurenlee Oct. 23 at 3:05 PM
$SCNX Let’s go $DRUG! I mean $SCNX
0 · Reply
simplifocused
simplifocused Oct. 23 at 2:48 PM
$OGEN NFA, can shock everyone like $BYND $DRUG https://stockscan.io/stocks/OGEN/forecast
0 · Reply
bobby_axelrod12
bobby_axelrod12 Oct. 23 at 2:42 PM
$SCNX is the next $DRUG
0 · Reply
bobby_axelrod12
bobby_axelrod12 Oct. 23 at 2:25 PM
$SCNX will follow $DRUG
0 · Reply
Latest News on DRUG
Bright Minds Biosciences: A Buy With A Major Catalyst In Q2 2025

Apr 16, 2025, 12:09 PM EDT - 6 months ago

Bright Minds Biosciences: A Buy With A Major Catalyst In Q2 2025


Bright Minds is Unaware of Any Material Changes

Oct 15, 2024, 9:09 PM EDT - 1 year ago

Bright Minds is Unaware of Any Material Changes


Bright Minds Announces Effective Date of Share Consolidation

Jul 11, 2023, 6:50 AM EDT - 2 years ago

Bright Minds Announces Effective Date of Share Consolidation


Bright Minds Announces Proposed Share Consolidation

Jun 22, 2023, 6:50 AM EDT - 2 years ago

Bright Minds Announces Proposed Share Consolidation


Bright Minds Announces Overnight Marketed Offering of Units

Aug 22, 2022, 7:05 PM EDT - 3 years ago

Bright Minds Announces Overnight Marketed Offering of Units


Bright Minds Biosciences Comments on Recent Trading Activity

Aug 18, 2022, 3:34 PM EDT - 3 years ago

Bright Minds Biosciences Comments on Recent Trading Activity


soulsearche
soulsearche Oct. 24 at 3:39 PM
$NEUP $TOVX run up is to distract biotech memes away from $NEUP.......$DRUG in making here. you heard it first here
1 · Reply
Builder46
Builder46 Oct. 23 at 3:28 PM
0 · Reply
topstockalerts
topstockalerts Oct. 23 at 3:17 PM
$DRUG Keep an eye for upcoming plays
0 · Reply
laurenlee
laurenlee Oct. 23 at 3:09 PM
$SCNX That was. $DRUG
0 · Reply
ghostrider007
ghostrider007 Oct. 23 at 3:07 PM
$SCNX $DRUG fkkk thatll be amazing
0 · Reply
laurenlee
laurenlee Oct. 23 at 3:06 PM
$SCNX $DRUG Two One hundred
0 · Reply
laurenlee
laurenlee Oct. 23 at 3:05 PM
$SCNX Let’s go $DRUG! I mean $SCNX
0 · Reply
simplifocused
simplifocused Oct. 23 at 2:48 PM
$OGEN NFA, can shock everyone like $BYND $DRUG https://stockscan.io/stocks/OGEN/forecast
0 · Reply
bobby_axelrod12
bobby_axelrod12 Oct. 23 at 2:42 PM
$SCNX is the next $DRUG
0 · Reply
bobby_axelrod12
bobby_axelrod12 Oct. 23 at 2:25 PM
$SCNX will follow $DRUG
0 · Reply
bobby_axelrod12
bobby_axelrod12 Oct. 23 at 2:25 PM
0 · Reply
laurenlee
laurenlee Oct. 23 at 2:25 PM
$SCNX Remember $DRUG
0 · Reply
laurenlee
laurenlee Oct. 23 at 1:43 PM
0 · Reply
dmenaze
dmenaze Oct. 23 at 12:46 PM
0 · Reply
laurenlee
laurenlee Oct. 23 at 12:45 PM
0 · Reply
invbond
invbond Oct. 23 at 11:15 AM
$SCNX In a sector where most small-caps dilute heavily just to stay alive, SCNX has done the opposite- it executed, cleaned up the balance sheet, and protected shareholders every step of the way. With a dual-FDA portfolio, national access, and a tight float, management has positioned the company perfectly for a major re-rating or strategic buyout opportunity. Achieved two full FDA drug approvals, Arbli™ and REZENOPY® while keeping total shares outstanding near ~23 M, an extraordinary feat for a small-cap biotech. Some of the moves management made just in Oct 2025 is very strategic in nature [ May be preparing for: Strategic Partnerships, Strategic global licencing rights for two FDA approved products or Strategic Acquisition ] SCNX is on move: 1. Gained two FDA-approved products 2. Eliminated all convertible debt & ELOC dilution 3. Secured non-dilutive financing with cash repayment only 4. Kept O/S light (~23 M) 5. Built a national commercial rollout (2,500 institutions + 100 M covered lives) Feels like something big is cooking like BUYOUT etc $DRUG
0 · Reply
randy212
randy212 Oct. 23 at 5:11 AM
$BYND $DRUG drug has 5 million free float while this has 70m and some data even suggests 300m. Be grateful if this sees 5-6$ again sell immediaetly.
0 · Reply
PaleWhale
PaleWhale Oct. 23 at 4:47 AM
$BYND could be the next $DRUG play.
0 · Reply
invbond
invbond Oct. 22 at 6:17 PM
$SCNX One lesser-highlighted strength of the TWO FDA APPROVALS : 1- Arbli & 2- Rezenopy 1. The company’s first-to-market position with its liquid formulation of losartan (Arbli™) gives it a unique niche in hypertension treatment. Many patients struggle with tablets (due to swallowing difficulties, pediatrics, geriatrics), so a ready-to-use liquid opens a differentiator. That niche can translate into premium pricing and formulary leverage (once positioned). Since they have the first mover advantage in that format, competitors may face higher hurdles to catch up. 2. Also, securing the exclusive U.S. rights to the opioid overdose rescue product (REZENOPY®) puts them into a $1.5B plus market (as previously noted). That gives a two-legged platform (cardio-liquid + rescue/emergency) which allows cross-leverage of commercial infrastructure, distribution, and formulary relationships. $DRUG
0 · Reply
tupelo3
tupelo3 Oct. 22 at 5:50 PM
$DRUG Does anyone know if there has been any news?
0 · Reply
invbond
invbond Oct. 22 at 3:34 PM
$SCNX Received TWO FDA APPROVALS : 1- Arbli & 2- Rezenopy $DRUG
0 · Reply
stoxx0007
stoxx0007 Oct. 22 at 1:41 PM
$DRUG = WTF is hoing on over her!??😯
0 · Reply